In summary, our results demonstrate that the promoter of ADAMTS19 is targeted by hypermethylation in a significant proportion of gastrointestinal cancers, particularly in BRAF-mutant cancers, and that this hypermethylation associates with transcriptional downregulation and reduces the in vitro migration capabilities of CRC cells. Here, ADAMTS19 is linked to colorectal carcinoma.